jackpot mega million usa
Acorda Therapeutics, Inc.(Nasdaq: ACOR) today announced its financial results for the first quarter 2008."Acorda made impressive progress in all areas of our business in the first quarter of 2008. We reported favorable results of our Fampridine-SR Thorough QT study, continued to deliver solid Zanaflex Capsules sales performance, and entered into a manufacturing agreement for our preclinical neuregulins program. In addition, we were successful in raising approximately $75 million in additional capital to fund our programs," said Ron Cohen, M. D., Acorda Therapeutics' President and CEO."As a result, we are well-positioned to address the important milestones ahead, particularly completion of our Phase 3 trial of Fampridine-SR which, if successful, will be followed by the filing of a new drug application, or NDA, in the first quarter of 2009. jackpot poker backgammon the-poker-guide onlineporno gamingonline wiki slots onlineplayer poker-on-line slots no download freeslots tod in bc win cards slots
